São Paulo, December 2020 – The third edition of the Scale-up B2B acceleration program organized by Endeavor has come to an end. The program was sponsored through the Synapsis program (www.eurofarma.com.br/synapsis) run by Eurofarma, the Brazilian pharmaceutical multinational company that invests the most in innovation in the country.
A total of 273 companies signed up to this edition. Of the 70 companies analyzed, 19 were selected to participate. In the end, eight companies developed projects with Eurofarma:
SenhaSegura: Optimize privileged user management in a computational and industrial environment.
Intellibrand: Ensure increased sales of our brands on our partners’ e-commerce platforms.
Intellibrand: Shorten consumers’ journey between searching for and purchasing a product.
RIO Analytics: Predictively identify performance losses or pre-failure conditions in industrial equipment.
Docket: Improve Debt Clearance Certificate management and monitoring, reducing costs.
Flipside: Generate insights to optimize information security awareness and educational actions.
Wehandle: Reduce legal, financial, and compliance risks through centralized management of third parties.
Digibee: Digitize the sales force expense reimbursement process.
“Another Eurofarma Synapsis ends with good results. In such a challenging year, we accelerated forward-looking scale-ups that are aligned with our challenges and bring open innovation to the company. These initiatives are paramount to help the company achieve more operational efficiency and agility in its areas. We are invested in providing continuous support to entrepreneurship,” said Helton Carvalho, Entrepreneurship and Digital Director at Eurofarma.
The program, which began in April, sought B2B solutions with the goal of forming a high-impact business network by proposing scalable and efficient solutions for various sectors. Throughout the months of the program, the selected entrepreneurs received individual and group mentoring with the Endeavor and Eurofarma networks, with a focus on diagnosing a company’s main growth challenges.
A virtual event held on December 9 showcased some of the ongoing cases and presented an overview of the program’s growth. Since 2018, when Synapsis was launched, Eurofarma has analyzed 145 companies, selected 39 scale-ups, and carried out 26 projects. Of these initiatives, 15 are still in progress, either in the pilot phase or fulfilling a contract with a specific area.
The beginning of expansion to Latin America was another important milestone for Eurofarma Synapsis. One of the projects was carried out at Eurofarma Uruguay, and employees from all units were involved in the project through Synapsis Talks, a series of discussions between Eurofarma executives and accelerated companies on subjects such as data security, innovation culture, and agile methodology.
About Eurofarma Group
As the first multinational pharmaceutical company with 100% Brazilian capital, the Eurofarma Group has been operating in the health industry since its establishment in 1972, producing and marketing innovative products and services to improve people’s quality of life. Focused on generating shared value, it operates in the areas of Prescription, Non-Prescription, and Generic Drugs, Hospital, Oncology and Veterinary. In Brazil alone, it offers 313 products, 649 dosage forms, serves 25 medical specialties and covers 89 therapeutic classes, which represent 81% of prescriptions in the brand market.
The Eurofarma Group has own operations in 20 countries, with an industrial park in Brazil and plants in 6 more Latin American countries. Reported sales totaled BRL 5.6 billion in 2019 and the Group employs over 7,000 employees.
EUROFARMA ON SOCIAL MEDIA
http://www.eurofarma.com.br
Facebook: @eurofarma | LinkedIn: @eurofarma
Instagram: @eurofarmalab | Twitter: @eurofarmaLab
Youtube: @eurofarmalab